Molecular pathogenesis and mechanisms of thyroid cancer
By Mingzhao Xing. Nature Reviews. Cancer, 2013
1,384 citations recorded by the source corpus.
Thyroid cancer is a common endocrine malignancy. There has been exciting progress in understanding its molecular pathogenesis in recent years, as best exemplified by the elucidation of the fundamental role of several major signalling pathways and related molecular derangements. Central to these mechanisms are the genetic and epigenetic alterations in these pathways, such as mutation, gene copy-number gain and aberrant gene methylation. Many of these molecular alterations represent novel diagnostic and prognostic molecular markers and therapeutic targets for thyroid cancer, which provide unprecedented opportunities for further research and clinical development of novel treatment strategies for this cancer.
Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Oncology
View Paper: https://www.semanticscholar.org/paper/5d69b8573f7783840b30ae4e48554d0f30ac48e9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Genetics
- Peter W. Laird
- S. Baylin
- Trey Ideker
- Y. Nikiforov
- J. Herman
- Benjamin J. Raphael
- Chip Stewart
- P. Park
In Oncology
- S. Baylin
- John N. Weinstein
- Peter W. Laird
- Trey Ideker
- Christopher Sander
- Nikolaus Schultz
- Mingzhao Xing
- Charles M. Perou
Citations in the corpus
- Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer (2013, background): “University of Sydney 95 44 (34-59) 20 (21.”
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014, background): “Chromosomal rearrangements and translocations contribute to PTC pathogenesis (Xing, 2013).”
- BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. (2014, background): “Biologically, BRAF mutation uses various molecular mechanisms to promote the aggressive tumor behaviors.(13) Because some of these tumor behaviors, particularly lymph node metastases, are the main source of PTC recurrence, it is not surprising that statistical adjustment for them could artificially ”